Vascular inflammation is a risk factor associated with brain atrophy and disease severity in Parkinson's disease: A case-control study
Open accessPublished version of a preprint
The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
Introduction . Systemic inflammation with elevated oxidative stress causing neuroinflammation is considered a major factor in the pathogenesis of Parkinson’s disease (PD). The interface between systemic circulation and the brain parenchyma is the blood-brain barrier (BBB), which also plays a role in maintaining neurovascular homeostasis. Vascular cell adhesion molecule-1 (VCAM-1) and microRNAs (miRNAs) regulate brain vessel endothelial function, neoangiogenesis, and, in turn, neuronal homeostasis regulation, such that their dysregulation can result in neurodegeneration, such as gray matter atrophy, in PD. Objective . Our aim was to evaluate the associations among specific levels of gray matter atrophy, peripheral vascular adhesion molecules, miRNAs, and clinical disease severity in order to achieve a clearer understanding of PD pathogenesis. Methods . Blood samples were collected from 33 patients with PD and 27 healthy volunteers, and the levels of VCAM-1 and several miRNAs in those samples were measured. Voxel-based morphometry (VBM) analysis was performed using 3 T magnetic resonance imaging (MRI) and SPM (Statistical Parametric Mapping software program). The associations among the vascular parameter, miRNAs, gray matter volume, and clinical disease severity measurements were evaluated by partial correlation analysis. Results . The levels of VCAM-1, miRNA-22, and miRNA-29a expression were significantly elevated in the PD patients. The gray matter volume atrophy in the left parahippocampus, bilateral posterior cingulate gyrus, fusiform gyrus, left temporal gyrus, and cerebellum was significantly correlated with increased clinical disease severity, the upregulation of miRNA levels, and increased vascular inflammation. Conclusion . Patients with PD seem to have abnormal levels of vascular inflammatory markers and miRNAs in the peripheral circulation, and these levels are correlated with specific brain volume changes. This study reinforces the associations among peripheral inflammation, the BBB interface, and gray matter atrophy in PD and further demonstrates that BBB dysfunction with neurovascular impairment may play an important role in PD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Vascular factors of Parkinson disease, modified by two hit vascular model references [6]. Peripheral inflammation with vascular factor-like hypertension, diabetes, aging process, and genetic factors for PD, leading to neurovascular unit (NUV) impairment (panel A) and BBB dysfunction (panel B). In panel A, abnormal neurovascular alterations cause changes in vascular perfusion in the cerebral blood flow and oxygen consumption and cerebral flow hypoperfusion with small vessel atherosclerosis, further leading to neoangiogenesis and neuroinflammation. In panel B, peripheral inflammation and the aging process can cause BBB dysfunction, with inflammatory factors infiltrating into the neurons and adjacent supporting tissue. Inflammation also causes neurotoxin accumulation in brain tissues and vascular damage that changes microvessel integrity, leading to microvascular hypoperfusion (oligaemia) and inducing neoangiogenesis, which in turn result in macrobrain structural changes like white matter hypertrophy and gray mater atrophy, which are in turn correlated with clinical disease progression. Abbreviations: VCAM-1: vascular cell adhesion molecule-1; UPDRS: Unified Parkinson's Disease Rating Scale; VBM: voxel-based morphology.](https://figures.cochat.ai/paper-figures/23f4db926d2a48c499f60a622840cb00/vascular-inflammation-is-a-risk-factor-associated-with-brain-atrophy-and-disease-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
Hirono, N., Mori, E., Ikejiri, Y., Imamura, T., Shimomura, T., Hashimoto, M., Yamashita, H., & Ikeda, M. (1997) · Brain and nerve · Cited by 21,038
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Older Adults' Reasons for Using Technology while Aging in Place
Peek, S. T. M., Luijkx, K. G., Rijnaard, M. D., Nieboer, M. E., van der Voort, C. S., Aarts, S., van Hoof, J., Vrijhoef, H. J. M., & Wouters, E. J. M. (2016) · Gerontology · doi:10.1159/000430949 · Cited by 19,690
Sensitivity and False Alarm Rate of a Fall Sensor in Long-Term Fall Detection in the Elderly
Kangas, M., Korpelainen, R., Vikman, I., Nyberg, L., & Jämsä, T. (2015) · Gerontology · doi:10.1159/000362720 · Cited by 18,909
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777 · cited 1×
“Parkinson’s disease (PD) has been characterized as a progressive neurological disorder without any available cure or preventative treatment [1, 2].”
BackgroundHughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
A fast diffeomorphic image registration algorithm
Ashburner, J. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.07.007 · Cited by 8,122
Daneman, R., & Prat, A. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020412 · Cited by 3,437 · cited 1×
“Under conditions of inflammation, the microglial release of proinflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interleukin- (IL-) 1β, and transforming growth factor-β, acts on the endothelium of BBB cells to stimulate the upregulation of VCAM-1 and ICAM-1, causing the transmigration of leukocyte…”
BackgroundThe Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders
Zlokovic, B. V. (2008) · Neuron · doi:10.1016/j.neuron.2008.01.003 · Cited by 3,280 · cited 1×
“Neurovascular status changes in the brain due to BBB dysfunction and aberrant angiogenesis cause white matter lesions (leukoaraiosis) [7], vessel regression, and brain hypoperfusion [21].”
Background
Research works printed but not linked: 1
- Sobhani A. Ebrahimi H. Ebrahimi A. VCAM-1 as a endothelial factor for diagnosis of dementia in Parkinson’s disease Joural of Neurology and Neuroscience 2018 9 1 p. 243
Cited by
Peripheral inflammation and blood–brain barrier disruption: effects and mechanisms
Huang, X., Hussain, B., & Chang, J. (2021) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13569 · Cited by 709
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Blood-Brain Barrier Dysfunction in CNS Disorders and Putative Therapeutic Targets: An Overview
Archie, S. R., Al Shoyaib, A., & Cucullo, L. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13111779 · Cited by 220
Chen, T., Dai, Y., Hu, C., Lin, Z., Wang, S., Yang, J., Zeng, L., Li, S., & Li, W. (2024) · Fluids and Barriers of the CNS · doi:10.1186/s12987-024-00557-1 · Cited by 189
Self-citationAsaoka, D., Xiao, J., Takeda, T., Yanagisawa, N., Yamazaki, T., Matsubara, Y., Sugiyama, H., Endo, N., Higa, M., Kasanuki, K., et al. (2022) · Journal of Alzheimer's Disease · doi:10.3233/jad-220148 · Cited by 156
Sofield, C. E., Anderton, R. S., & Gorecki, A. M. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46050256 · Cited by 124
Liu, Z., Fan, Q., Wu, S., Wan, Y., & Lei, Y. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01462-4 · Cited by 112
“The antioxidant effects as well as anti-inflammatory of high-density lipoprotein cholesterol (HDL-C) are well known, and reduced risks of HDL-C are relevant to systemic inflammation and endothelial cell dysfunction, thus participating in the progression of PD [4, 10].”
BackgroundCheng, G., Liu, Y., Ma, R., Cheng, G.-P., Guan, Y., Chen, X.-J., Wu, Z., & Chen, T.-K. (2022) · Nano-Micro Letters · doi:10.1007/s40820-022-00847-z · Cited by 109
Small-cell lung cancer brain metastasis: From molecular mechanisms to diagnosis and treatment
Zhu, Y., Cui, Y., Zheng, X., Zhao, Y. M., & Sun, G. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2022.166557 · Cited by 108
Ponce-Lopez, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094209 · Cited by 75
Promising use of metformin in treating neurological disorders: biomarker-guided therapies
Loan, A., Syal, C., Lui, M., He, L., & Wang, J. (2023) · Neural Regeneration Research · doi:10.4103/1673-5374.385286 · Cited by 53
Blossom, V., Ullal, S. D., D’Souza, M. M., Ranade, A. V., Kumar, N. A., & Rai, R. (2025) · 3 Biotech · doi:10.1007/s13205-025-04468-2 · Cited by 64
Hadisurya, M., Li, L., Kuwaranancharoen, K., Wu, X., Lee, Z.-C., Alcalay, R. N., Padmanabhan, S., Tao, W. A., & Iliuk, A. B. (2023) · Communications Medicine · doi:10.1038/s43856-023-00294-w · Cited by 48
NOX-induced oxidative stress is a primary trigger of major neurodegenerative disorders
Zilberter, Y., Tabuena, D. R., & Zilberter, M. Y. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102539 · Cited by 37
Macdonald, D. W., Berdoy, M., & Webster, J. P. (2015) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780198745501.003.0011 · Cited by 27
Ritson, M., Wheeler-Jones, C. P. D., & Stolp, H. B. (2024) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2024.578363 · Cited by 26
Yang, Y., Lin, T., & Huang, Y. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.175302 · Cited by 23
Altered protein secretion in Batten disease
Huber, R. J. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.049152 · Cited by 25
Li, X., Hao, D., Qu, M., Zhang, M., Ma, A.-B., Pan, X., & Ma, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.795539 · Cited by 20
Wang, L., Liu, C., Shao, Y., Jin, H., Mao, C., & Chen, J. (2022) · Neuroscience Letters · doi:10.1016/j.neulet.2022.136692 · Cited by 16
Agrawal, S., Leurgans, S. E., Nag, S., Oveisgharan, S., Barnes, L. L., Bennett, D. A., Buchman, A. S., & Schneider, J. A. (2023) · Neurology · doi:10.1212/wnl.0000000000207497 · Cited by 16
The role of peripheral inflammation-related biomarkers in distinguishing Parkinson's disease
Zhang, Z., Wang, Y., Wang, J., Cai, Y., Liu, P., Liu, S., Wu, J., & Xie, X. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.106102 · Cited by 17
miRNAs in neurodegenerative diseases: from target screening to precision therapy
Liao, D., Zhang, Y., Li, S., Tang, H., & Bai, X. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08051-8 · Cited by 14
Self-citationInvolvement of noncoding RNA in blood-brain barrier integrity in central nervous system disease
Liu, X., Shen, L., Han, B., & Yao, H. (2021) · Non-coding RNA Research · doi:10.1016/j.ncrna.2021.06.003 · Cited by 14
Cerebellar microglia: On the edge between neuroinflammation and neuroregulation
Dukhinova, M., Guo, J., Shen, E.-W., Liu, W., Huang, W., Shen, Y., & Wang, L. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00550 · Cited by 16
Wang, L., Xiong, X., Liu, J.-Q., Liu, R.-S., Liao, J., Li, F., Lu, S.-X., Wang, W., Zhuo, L.-H., & Li, H.-W. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12934-3 · Cited by 14
Maazouzi, M., Rasheed, M., Mbarek, L., Wang, X., Liang, J., Ma, H., Chen, Z., & Deng, Y. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70031 · Cited by 12
Association between serum myeloperoxidase enzyme activity and Parkinson’s disease status
Fernández‐Espejo, E., Guerra, M.-D.-M., & Castellano, S. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-00941-0 · Cited by 15
HDAC4 Inhibitors as Antivascular Senescence Therapeutics
Huang, C., Lin, Z., Liu, X., Ding, Q., Cai, J., Zhang, Z., Rose, P., & Zhu, Y. Z. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/3087916 · Cited by 11
Self-citationIncreased PRR14 and VCAM-1 level in serum of patients with Parkinson's disease
Zheng, H., Wang, T., Shi, C., Fan, L., Su, Y., Fan, Y., Li, X., Yang, J., Mao, C., & Xu, Y. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.993940 · Cited by 11
Upregulation of microRNAs correlates with downregulation of HERV-K expression in Parkinson’s disease
Simula, E. R., Jasemi, S., Paulus, K., & Sechi, L. A. (2024) · Journal of NeuroVirology · doi:10.1007/s13365-024-01234-7 · Cited by 6
Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes
Ma, D., Li, S., Shi, J., Liang, Y., Hu, Z., Hao, X., Li, M., Guo, M.-N., Zuo, C., Yu, W.-K., et al. (2023) · Movement Disorders · doi:10.1002/mds.29598 · Cited by 7
Self-citationReport on the Myomatrix Conference April 22–24, 2012, University of Nevada, Reno, Nevada, USA
Rutkowski, A., Bönnemann, C. G., Brown, S., Þorsteinsdóttir, S., Dominov, J. A., Rüegg, M. A., Matter, M. L., Guttridge, D. C., Crosbie, R. H., Kardon, G., et al. (2012) · Neuromuscular Disorders · doi:10.1016/j.nmd.2012.06.353 · Cited by 4
Jiao, X., Li, R., Li, L., Wu, X., Wang, L. R., Yang, F., Zhang, F., Liu, J., Ji, X., & Guo, X. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71042 · Cited by 1
Microalbuminuria as a potential biomarker for Parkinson’s disease severity: A hypothesis
Meléndez‐Flores, J. D., Cavazos-Benítez, A. C., & Estrada-Bellmann, I. E. (2021) · Medical Hypotheses · doi:10.1016/j.mehy.2021.110510 · Cited by 1
Kim, S. H., Park, M., & Jeong, S. H. (2024) · The Journals of Gerontology Series A · doi:10.1093/gerona/glae081 · Cited by 2
Melas, K., Talevi, V., Imtiaz, M. A., Krüger, D. M., Pena‐Centeno, T., Fischer, A., Aziz, N. A., & Breteler, M. M. B. (2026) · Molecular Psychiatry · doi:10.1038/s41380-026-03611-6
Metadata
- Authors
- Yu, C.-C., Chen, H.-L., Chen, M.-H., Lu, C.-H., Tsai, N.-W., Huang, C.-C., Chang, Y.-Y., Li, S.-H., Chen, Y.-S., Chiang, P.-L., & Lin, W.-C.
- Affiliations
- Kaohsiung Chang Gung Memorial Hospital (TW)
- Corresponding author
- Lin, Wei-Che
- ORCID
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2020-07-14
- Volume
- 2020
- Pages
- 1-12
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- PMC
- PMC7376437
- OpenAlex
- W3043199888
- Cited by
- 37
- References
- 84
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 7 · 2023: 5 · 2022: 7 · 2021: 7 · 2020: 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
- Research Square (acceptedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Chang Gung Memorial Hospital (CMRPG8E0621, CMRPG8C0021, CMRPG890801, CMRPG8B0831, CMRPG891511, 104-2314-B-182A-053, 103-2314-B-182A-010-MY3)
- National Science Council (CMRPG8E0621, CMRPG8C0021, CMRPG890801, CMRPG8B0831, CMRPG891511, 104-2314-B-182A-053, 103-2314-B-182A-010-MY3)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- Parkinson's disease, vascular inflammation, gray matter atrophy, VCAM-1, microRNA, miR-22, miR-29a, blood-brain barrier dysfunction, neurovascular unit, disease severity, peripheral inflammation, neuroinflammation, brain volume changes
- MeSH terms
- Atrophy, Brain, Female, Humans, Inflammation, Male, Middle Aged, Parkinson Disease, Risk Factors, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.